US Patent

US8754065 — Tenofovir alafenamide hemifumarate

Method of Use · Assigned to Gilead Sciences Inc · Expires 2032-08-15 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a hemifumarate form of tenofovir alafenamide, used in antiviral therapy.

USPTO Abstract

A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-257 — bictegravir-sodium
U-257 — bictegravir-sodium
U-1663 — Emtriva
U-257 — Tybost
U-999 — tenofovir-alafenamide-fumarate
U-2352 — Tybost
U-257 — Emtriva
U-1259 — Emtriva

Patent Metadata

Patent number
US8754065
Jurisdiction
US
Classification
Method of Use
Expires
2032-08-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.